Opinion on Antifungals

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: focusing on high performers

Published By Datamonitor
17 Oct 2000
CommentWire
CommentWire

Intermune: Niche markets and beyond

Published By Datamonitor
10 Apr 2001
CommentWire
CommentWire

Antifungals: empiric therapy supported in newborns

Published By Datamonitor
15 May 2001
CommentWire
CommentWire

Antifungals: money spent is money saved

New antifungal drugs, such as Merck's Cancidas and Pfizer's Vfend, can help treat serious fungal disease in patients with poorly functioning immune systems. Although they are seemingly more expensive than their predecessors, they can potentially reduce the length of hospital stay and the need to treat adverse effects, thereby cutting the overall costs.

Published By Datamonitor
17 Feb 2003
ResearchWire
ResearchWire

Pfizer: leader of the pack in antifungals

Published By Datamonitor
28 Feb 2003
Expert View
Expert View

Fungal Infections: Maximizing potential in a saturated market

Superficial fungal infections are found on the peripheral surfaces of the body such as the skin, hair and nails. In spite of posing no threat of mortality, these infections are very common and represent an attractive potential market. However, low presentation rates and frequent misdiagnosis mean that only a small proportion of this patient potential is currently being realized. <BR />

Published By Datamonitor
06 Jun 2003
CommentWire
CommentWire

Pfizer: Diflucan's pediatric exclusivity delaying the inevitable

Pfizer's [PFZ.L] leading antifungal medicine Diflucan has had its six month marketing exclusivity upheld by the US District Court of Washington. This ruling only gives Diflucan short-term protection against genericization. In the longer term, Pfizer will have to rely on its new antifungal product, Vfend, to maintain market share.

Published By Datamonitor
16 Mar 2004
CommentWire
CommentWire

Systemic antifungals: growing rapidly

The leading azole class of antifungal drugs, worth $1.5 billion in 2003, will remain the market leader, contributing an estimated 50% of total sales in 2014. However, overall growth will primarily be driven by the novel echinocandin class, which is expected to experience a CAGR of 11.2% in the ten years to 2014.

Published By Datamonitor
12 May 2004
Expert View
Expert View

Mycamine - bolstering the antifungal armory

Fujisawa's Mycamine is the second product in the novel class of the echinocandins to be approved for use in the US. Mycamine has witnessed rapid uptake in its first market, Japan, generating $106 million of sales in 2004. Indeed, the staggered geographic launch of the drug, made necessary by delays in gaining approval in the US and EU, may actually contribute to its future commercial success.

Published By Datamonitor
23 Mar 2005
CommentWire
CommentWire

Accentia: uncertain role for SinuNase

Accentia believes that it has evidence to support a theory that most, if not all, cases of chronic sinusitis are caused by fungal-induced inflammation. Preliminary analysis of samples taken as part of a Phase III trial for one of the company's developmental compounds suggest a link, but the role of the drug in disease management is less clear.

Published By Datamonitor
11 Sep 2007

« | 1 | 2 | » »|

No help is available.